אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

medlab pty ltd - colecalciferol,menaquinone 7 -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

natural bio pty limited - colecalciferol, quantity: 83.3 microgram/ml - spray - excipient ingredients: peppermint oil; citric acid; potassium sorbate; maize oil; purified water; glycerol; steviol glycosides; peg-40 hydrogenated castor oil - maintain/support general health and wellbeing ; anti-inflammatory/relieve inflammation ; maintain/support bone health ; maintain/support bone mass/density/integrity ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; maintain/support healthy immune system function ; enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support lung health ; maintain/support healthy mucous membranes/mucous tissue of the respiratory tract

סינגפור - אנגלית - HSA (Health Sciences Authority)

pfizer private limited - crm197 protein; pneumococcal polysaccharide serotype 1 (conjugate); pneumococcal polysaccharide serotype 14 (conjugate); pneumococcal polysaccharide serotype 18c (conjugate); pneumococcal polysaccharide serotype 19a (conjugate); pneumococcal polysaccharide serotype 19f (conjugate); pneumococcal polysaccharide serotype 23f (conjugate); pneumococcal polysaccharide serotype 3 (conjugate); pneumococcal polysaccharide serotype 4 (conjugate); pneumococcal polysaccharide serotype 5 (conjugate); pneumococcal polysaccharide serotype 6a (conjugate); pneumococcal polysaccharide serotype 6b (conjugate); pneumococcal polysaccharide serotype 7f (conjugate); pneumococcal polysaccharide serotype 9v (conjugate) - injection, suspension - 32mcg - crm197 protein 32mcg; pneumococcal polysaccharide serotype 1 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 14 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 18c (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 19a (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 19f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 23f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 3 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 4 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 5 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 6a (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 6b (conjugate) 4.4mcg; pneumococcal polysaccharide serotype 7f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 9v (conjugate) 2.2mcg

סינגפור - אנגלית - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d; diphtheria toxoid (dt) carrier protein; polysaccharide (ps); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae); tetanus toxoid (tt) carrier protein - injection, suspension - 1 μg ps1; 1.11-1.67 μg pd/dose - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d 1 μg ps1; 1.11-1.67 μg pd/dose; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d 1 μg ps14; 1.00-1.82 μg pd/dose; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid 3 μg ps18c; 5.45-10.00 μg tt/dose; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid 3 μg ps19f; 3.33-6.00 μg dt/dose; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d 1 μg ps23f; 0.39-0.74 μg pd/dose; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d 3 μg ps4; 3.33-6.67 μg pd/dose; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d 1 μg ps5; 0.67-1.25 μg pd/dose; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d 1 μg ps6b; 0.56-0.95 μg pd/dose; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d 1 μg ps7f; 0.87-1.43 μg pd/dose; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d 1 μg ps9v; 1.00-1.82 μg pd/dose; diphtheria toxoid (dt) carrier protein 3-6 μg dt/dose (total dt content); polysaccharide (ps) 16 μg/dose (total ps content); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae) 9-16 μg pd/dose (total pd content); tetanus toxoid (tt) carrier protein 5-10 μg/dose (total tt content)

סינגפור - אנגלית - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hpv-16 l1; hpv-18 l1 - injection, suspension - 20 μg/0.5ml - hpv-16 l1 20 μg/0.5ml; hpv-18 l1 20μg/0.5ml

ישראל - אנגלית - Ministry of Health

henry schein shvadent (2009 ) ltd - epinephrine as bitartrate; lidocaine as monohydrate - solution for injection - lidocaine as monohydrate 20 mg/ml; epinephrine as bitartrate 10 mcg/ml - lidocaine - lidocaine - production of local anesthesia by nerve block or infiltration technique.

ישראל - אנגלית - Ministry of Health

a. levy dental co. ltd, israel - epinephrine as bitartrate; lidocaine hydrochloride ( as monohydrate) - solution for injection - epinephrine as bitartrate 0.01 mg/ml; lidocaine hydrochloride ( as monohydrate) 20 mg/ml - amides - production of local anesthesia by nerve block or infiltration technique.

ישראל - אנגלית - Ministry of Health

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

סינגפור - אנגלית - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 150mg - omalizumab 150mg